s6y

CERO THERAPEUTICS HOLDINGS, INC.

Ticker
CERO, CEROW
CIK
1870404
Industry
Biological Products, (No Diagnostic Substances)
Formerly
CERO THERAPEUTICS HOLDINGS, INC., PHOENIX BIOTECH ACQUISITION CORP.

Financials 31

  1. 10-Q Quarterly Report for period ending Sep 30, 2026
  2. 10-Q Quarterly Report for period ending Jun 30, 2026
  3. 10-Q Quarterly Report for period ending Mar 31, 2026
  4. 10-K/A Annual Report for period ending Dec 31, 2025
  5. 10-K Annual Report for period ending Dec 31, 2025
  6. NT 10-K Notice under Rule 12b25 of inability to timely file all or part of a Form 10-K, 10-KSB, or 10-KT for period ending Dec 31, 2025
  7. 10-Q Quarterly Report for period ending Sep 30, 2025
  8. NT 10-Q Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB for period ending Sep 30, 2025
  9. 10-Q Quarterly Report for period ending Jun 30, 2025
  10. NT 10-Q Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB for period ending Jun 30, 2025

All 31 financials filings

News 80

  1. 8-K Current report filing
  2. 8-K Current report filing
  3. 8-K Current report filing
  4. 8-K Current report filing
  5. 8-K Current report filing
  6. 8-K Current report filing
  7. 8-K Current report filing
  8. 8-K Current report filing
  9. 8-K Current report filing
  10. 8-K Current report filing

All 80 news filings

Ownership 118

  1. 4 Statement of changes in beneficial ownership of securities
  2. 3 Initial statement of beneficial ownership of securities
  3. 4 Statement of changes in beneficial ownership of securities
  4. 4 Statement of changes in beneficial ownership of securities
  5. 4 Statement of changes in beneficial ownership of securities
  6. 4 Statement of changes in beneficial ownership of securities
  7. 4 Statement of changes in beneficial ownership of securities
  8. 4 Statement of changes in beneficial ownership of securities
  9. 4 Statement of changes in beneficial ownership of securities
  10. 4 Statement of changes in beneficial ownership of securities

All 118 ownership filings

Prospectus 122

  1. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  2. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  3. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  4. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  5. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  6. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  7. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  8. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  9. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  10. 424B3 Prospectus filed pursuant to Rule 424(b)(3)

All 122 prospectus filings

Proxies 25

  1. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  2. DEF 14A Definitive proxy statements
  3. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  4. DEF 14A Definitive proxy statements
  5. PRER14A Preliminary revised proxy soliciting materials
  6. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  7. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  8. DEFR14A Definitive revised proxy soliciting materials
  9. DEF 14A Definitive proxy statements
  10. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition

All 25 proxies filings

Other 70

  1. SCHEDULE 13G/A
  2. 25-NSE Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
  3. SCHEDULE 13G
  4. EFFECT Notice of Effectiveness
  5. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  6. EFFECT Notice of Effectiveness
  7. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  8. SCHEDULE 13G/A
  9. UPLOAD Letter (PDF)
  10. EFFECT Notice of Effectiveness

All 70 other filings